<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715611</url>
  </required_header>
  <id_info>
    <org_study_id>08-053</org_study_id>
    <nct_id>NCT00715611</nct_id>
  </id_info>
  <brief_title>Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma</brief_title>
  <official_title>Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      For patients with this type of cancer, the standard of care is treatment with chemotherapy.&#xD;
      Radiation therapy is typically not used. This is because radiation to the entire lining of&#xD;
      the lung has many side effects that are often severe including damage to the lung&#xD;
      (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy&#xD;
      (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy.&#xD;
      This type of radiation therapy specifically targets the lining of the lung, where you have&#xD;
      your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is&#xD;
      to test the safety and implementation of standard pleurectomy/decortication (removal of the&#xD;
      surface lining of the lung) and standard chemotherapy followed by IMRT performed at other&#xD;
      centers. Patients will undergo pleurectomy/decortication chemotherapy and hemithoracic&#xD;
      pleural IMRT to the pleura in patients with malignant pleural mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 11, 2008</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients ≥ grade 3 pneumonitis</measure>
    <time_frame>2 years</time_frame>
    <description>Grade 3 pneumonitis is defined as symptomatic, interfering with ADL's and requiring oxygen support as defined by the NCI Common Terminology Criteria (CTC) version 4.0 for toxicity and Adverse Event reporting.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a multicenter phase II toxicity study of pleurectomy/decortication (P/D) followed by adjuvant chemotherapy and Intensity Modulated Radiation Therapy (IMRT) to the pleura in patients with malignant pleural mesothelioma. Alternatively, chemotherapy may be administered in the neoadjuvant setting prior to P/D, followed by IMRT. Patients deemed resectable at the time of enrollment will undergo P/D with the goal of a macroscopic complete resection (MCR). Those with disease progression or severe toxicity will stop chemotherapy and undergo a PET scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pleurectomy/Decortication</intervention_name>
    <description>Pleurectomy/decortication will be performed as per standard technique</description>
    <arm_group_label>1</arm_group_label>
    <other_name>(P/D)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed and cisplatin or carboplatin</intervention_name>
    <description>The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity Modulated Radiation Therapy</intervention_name>
    <description>IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent to participate on the study&#xD;
&#xD;
          -  Patients must have a pathologically confirmed diagnosis either at MSKCC or at the&#xD;
             participating site of stage I-III malignant pleural mesothelioma&#xD;
&#xD;
          -  Epithelioid or biphasic histology subtype (Note: patients with biphasic histology can&#xD;
             have &lt; 10% sarcomatoid)&#xD;
&#xD;
          -  No evidence of metastatic disease.&#xD;
&#xD;
          -  Patient age ≥ 18 years but ≤ 80 years at the time of consent.&#xD;
&#xD;
          -  Karnofsky performance status ≥ 80%&#xD;
&#xD;
          -  Pulmonary Function Tests:&#xD;
&#xD;
               1. For all patients: DLCO &gt; 40% predicted (corrected for Hgb)&#xD;
&#xD;
               2. For patients enrolled post-P/D, only: FEV1 &gt;/= 35% (corrected for Hgb) (Note:&#xD;
                  patients enrolled prior to P/D will have PFTs repeated pre-IMRT. If this criteria&#xD;
                  is not met, they will be removed from study)&#xD;
&#xD;
          -  In cases of concern about decreased renal function and potential high radiation dose&#xD;
             to the kidneys, an optional nuclear medicine kidney function scan may be performed&#xD;
             prior to radiation therapy to determine the functional contribution of each kidney.&#xD;
&#xD;
          -  Patient enrolled prior to chemotherapy must have adequate organ function as indicated&#xD;
             by the following laboratory values:&#xD;
&#xD;
               1. Absolute neutrophil count ≥1.5 K/mcL&#xD;
&#xD;
               2. Platelets ≥100 K/mcL&#xD;
&#xD;
               3. Serum total bilirubin ≤ 1.5 X ULN&#xD;
&#xD;
               4. AST (SGOT) or ALT (SGPT) ≤ 3.0 X ULN Note: patients enrolled after chemotherapy&#xD;
                  do not have to meet the above criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt; 10% Sarcomatoid or desmoplastic histology&#xD;
&#xD;
          -  Continuous oxygen use&#xD;
&#xD;
          -  Prior nephrectomy on the contralateral side of MPM&#xD;
&#xD;
          -  Prior intrapleural therapy (except pleurodesis) or intrapleural therapy at the time of&#xD;
             P/D (i.e.: intrapleural chemotherapy, photodynamic therapy, intrapleural betadine)&#xD;
&#xD;
          -  Prior thoracic radiation therapy preventing hemithoracic pleural IMRT&#xD;
&#xD;
          -  Bulky disease in the fissure preventing lung-sparing pleural IMRT&#xD;
&#xD;
          -  Patients undergoing extrapleural pneumonectomy&#xD;
&#xD;
          -  Patients with an active infection that require systemic antibiotics, antiviral, or&#xD;
             antifungal treatments&#xD;
&#xD;
          -  Patients with a concurrent active malignancy (except squamous or basal cell carcinoma&#xD;
             of the skin)&#xD;
&#xD;
          -  Patients with serious unstable medical illness&#xD;
&#xD;
          -  Presence of third space fluid that cannot be controlled by drainage&#xD;
&#xD;
          -  For patients who develop or have baseline clinically significant pleural effusions&#xD;
             before or during initiation of pemetrexed therapy; consideration should be given to&#xD;
             drain the effusion prior to chemotherapy administration&#xD;
&#xD;
          -  No acute congestive heart failure&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Men or women not using effective contraception&#xD;
&#xD;
        Reproductive risks Patients should not become pregnant or father a baby while on this study&#xD;
        because the drugs in this study can affect an unborn baby. Women should not breast-feed a&#xD;
        baby while on this study. Women of childbearing age will be counseled to use birth control&#xD;
        while on this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Rimner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Rimner, MD</last_name>
    <phone>212-639-6025</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie Rusch, MD</last_name>
    <phone>212-639-5873</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradford Perez, MD</last_name>
      <phone>888-663-3488</phone>
    </contact>
    <investigator>
      <last_name>Bradford Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Mak, MD</last_name>
      <phone>617-632-3591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Garces, MD</last_name>
      <phone>507-538-3270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering West Harrison</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
    <contact_backup>
      <last_name>Valerie Rusch, MD</last_name>
      <phone>212-639-5873</phone>
    </contact_backup>
    <investigator>
      <last_name>Andreas Rimner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rimner, MD</last_name>
      <phone>212-639-6025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gomez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pemetrexed</keyword>
  <keyword>cisplatin</keyword>
  <keyword>IMRT</keyword>
  <keyword>PLEURA</keyword>
  <keyword>Malignant</keyword>
  <keyword>08-053</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

